The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China
The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
In this study cohorts, naïve or csDMARDs-IR patients are treated with different csDMARDs combination or TNF inhibitors for 24 weeks to get remission in clinical. The biomarkers in their plasma and synovial fluid and tissue specimens from RA patients are screened to predict the efficacy of specific treatment.
Inclusion Criteria:
-
1.Patients with RA who meet ACR 1987 rheumatoid arthritis classification criteria or ACR/EULAR 2010 rheumatoid arthritis Classification Criteria and have knee dysfunction.
ACR 1987 rheumatoid arthritis classification criteria
ACR/EULAR 2010 rheumatoid arthritis Classification Criteria
Involved joints
- 1 large joint (0 points)
Serological indicators
Acute chronotropic reactants
Duration of synovitis
<6 weeks (0 points)
≥6 weeks (1 point)
2.Patients with OA who meet the 1995 Classification Criteria for OA and have knee dysfunction 1995 Classification Criteria for Osteoarthritis of the Knee Clinical criteria
a. Knee pain most of the time in the last 1 month b. Bone rubbing sound c, morning stiffness ≤ 30 minutes d, age ≥ 38 years e, with bony enlargement Knee OA can be diagnosed if a+b+c+d or a+b+e is met
3.Age-sex matched healthy volunteers who checked in our hospital.
4.Age > 18 years old;
5.Voluntarily participate in this study and sign an informed consent form
Exclusion Criteria:
shuqiang@sdu.edu.cn0086-0531-82169654
sdrenbingbing@163.com0086-18765361979